PDCD1 and cancer: We next evaluated the effectiveness of UMCD6 in enhancing killing of cancer cells representative of a cancer type, non–small cell lung carcinoma (NSCLC), in which PD-1/PD-L1–targeted checkpoint inhibitor immunotherapy is currently widely used.